| 1 |
34797531 | Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. | 2022 Feb |
1 |
| 2 |
35044836 | TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma. | 2022 Jan |
1 |
| 3 |
35089671 | Current Frontline Treatment of Diffuse Large B-Cell Lymphoma. | 2022 Jan 20 |
1 |
| 4 |
35297262 | Colonic infiltration of chronic lymphocytic leukemia with Hodgkin Reed Sternberg-like cells. | 2022 Mar 17 |
1 |
| 5 |
35451406 | Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma. | 2022 Mar 11 |
1 |
| 6 |
35468783 | Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. | 2022 Apr 25 |
1 |
| 7 |
35573753 | COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma. | 2022 Apr |
1 |
| 8 |
33348022 | Endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity may be therapeutically targeted by natural and chemical compounds: A review. | 2021 Feb |
1 |
| 9 |
33436910 | Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy. | 2021 Jan 12 |
1 |
| 10 |
33555941 | Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. | 2021 Apr 20 |
1 |
| 11 |
33591324 | A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. | 2021 Feb 23 |
1 |
| 12 |
33592897 | Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report. | 2021 Feb 5 |
1 |
| 13 |
33625586 | Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. | 2021 Sep |
1 |
| 14 |
33688781 | Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population. | 2021 Aug |
1 |
| 15 |
33734921 | R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis. | 2021 Jun |
1 |
| 16 |
33857568 | Study of ER stress and apoptotic proteins in the heart and tumor exposed to doxorubicin. | 2021 Jun |
6 |
| 17 |
33944646 | Burden of illness and treatment patterns among patients with peripheral T-cell lymphoma in the US healthcare setting. | 2021 Jul |
1 |
| 18 |
34120620 | Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma. | 2021 Jun 13 |
1 |
| 19 |
34124276 | Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration. | 2021 |
1 |
| 20 |
34362493 | [Doxorubicin Hydrochloride Liposome-Based CHOP Regimen in the Initial Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Study]. | 2021 Aug |
2 |
| 21 |
34565287 | Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. | 2021 Dec |
1 |
| 22 |
34586105 | Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma. | 2021 Sep |
1 |
| 23 |
34732441 | Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma. | 2021 Nov |
2 |
| 24 |
34745610 | Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. | 2021 |
2 |
| 25 |
34765356 | Vincristine-Induced Bilateral Vocal Cord Palsy in an Adult Male With Diffuse Large B-Cell Lymphoma. | 2021 Oct |
1 |
| 26 |
34943000 | Endoplasmic Reticulum Stress Promotes iNOS/NO and Influences Inflammation in the Development of Doxorubicin-Induced Cardiomyopathy. | 2021 Nov 26 |
2 |
| 27 |
34990525 | Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. | 2021 Dec 30 |
1 |
| 28 |
31774307 | Doxorubicin-induced oxidative stress differentially regulates proteolytic signaling in cardiac and skeletal muscle. | 2020 Feb 1 |
1 |
| 29 |
31902733 | Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes. | 2020 Feb |
1 |
| 30 |
32042095 | Identification of gene modules associated with survival of diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. | 2020 Oct |
1 |
| 31 |
32112707 | Double-Hit and Triple-Hit Follicular Lymphoma. | 2020 Apr 15 |
1 |
| 32 |
32187361 | Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. | 2020 May 14 |
1 |
| 33 |
32250167 | ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. | 2020 May |
1 |
| 34 |
32417940 | Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. | 2020 Jul |
1 |
| 35 |
32505213 | A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. | 2020 Jun 6 |
1 |
| 36 |
32648457 | Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center. | 2020 Jul |
1 |
| 37 |
32730183 | Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). | 2020 Oct 10 |
1 |
| 38 |
32915975 | Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma. | 2020 Sep 22 |
1 |
| 39 |
33091357 | A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. | 2020 Nov |
1 |
| 40 |
33093947 | ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. | 2020 |
1 |
| 41 |
33116822 | Splenic Diffuse Red Pulp Small B-Cell Lymphoma with Gastrointestinal Hemorrhage: A Case Report and Literature Review. | 2020 |
1 |
| 42 |
33230132 | Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas. | 2020 Nov 23 |
1 |
| 43 |
33269174 | DA-REPOCH Versus R-CHOP for the Treatment of Activated B-Cell Subtype Diffuse Large B-Cell Lymphoma: A Community Center Experience. | 2020 Nov 26 |
1 |
| 44 |
33317571 | New agents and regimens for diffuse large B cell lymphoma. | 2020 Dec 14 |
1 |
| 45 |
33323828 | R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms. | 2020 Dec 8 |
1 |
| 46 |
30552901 | 2-Bromopalmitate sensitizes osteosarcoma cells to adriamycin-induced apoptosis via the modulation of CHOP. | 2019 Feb 5 |
3 |
| 47 |
30850561 | Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies. | 2019 Sep |
1 |
| 48 |
31118164 | R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma. | 2019 Jul 18 |
1 |
| 49 |
31185769 | Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database. | 2019 Dec |
1 |
| 50 |
31222719 | Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. | 2019 Oct |
1 |